143 related articles for article (PubMed ID: 10871787)
1. Serum auto antibodies presence in multiple sclerosis patients treated with beta-interferon 1a and 1b.
Speciale L; Saresella M; Caputo D; Ruzzante S; Mancuso R; Calvo MG; Guerini FR; Ferrante P
J Neurovirol; 2000 May; 6 Suppl 2():S57-61. PubMed ID: 10871787
[TBL] [Abstract][Full Text] [Related]
2. [Development of binding antibodies to interferon-beta during treatment of multiple sclerosis with different types of interferon-beta].
Bartosik-Psujek H; Mitosek-Szewczyk K; Belniak E; Stelmasiak Z
Pol Merkur Lekarski; 2004 Jul; 17(97):28-32. PubMed ID: 15559606
[TBL] [Abstract][Full Text] [Related]
3. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
[TBL] [Abstract][Full Text] [Related]
4. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
Barbero P; Verdun E; Bergui M; Pipieri A; Clerico M; Cucci A; Ricci A; Bergamasco B; Durelli L
J Neurol Sci; 2004 Jul; 222(1-2):13-9. PubMed ID: 15240190
[TBL] [Abstract][Full Text] [Related]
5. Effects of rIFN-beta-1b on serum circulating ICAM-1 in relapsing remitting multiple sclerosis and on the membrane-bound ICAM-1 expression on brain microvascular endothelial cells.
Trojano M; Defazio G; Avolio C; Paolicelli D; Giuliani F; Giorelli M; Livrea P
J Neurovirol; 2000 May; 6 Suppl 2():S47-51. PubMed ID: 10871785
[TBL] [Abstract][Full Text] [Related]
6. Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis.
Cocco E; Marchi P; Floris G; Mascia MG; Deriu M; Sirca A; Mamusa E; Lai M; Mura M; Mallarini G; Marrosu MG
Funct Neurol; 2006; 21(3):145-9. PubMed ID: 17049133
[TBL] [Abstract][Full Text] [Related]
7. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
[TBL] [Abstract][Full Text] [Related]
8. Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study.
Patti F; Pappalardo A; Florio C; Politi G; Fiorilla T; Reggio E; Reggio A
Acta Neurol Scand; 2006 Apr; 113(4):241-7. PubMed ID: 16542163
[TBL] [Abstract][Full Text] [Related]
9. High prevalence of anti-phospholipid antibodies and anti-thyroglobulin antibody in patients with hepatitis C virus infection treated with interferon-alpha.
Matsuda J; Saitoh N; Gotoh M; Gohchi K; Tsukamoto M; Syoji S; Miyake K; Yamanaka M
Am J Gastroenterol; 1995 Jul; 90(7):1138-41. PubMed ID: 7611213
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy.
Fainardi E; Rizzo R; Melchiorri L; Castellazzi M; Govoni V; Caniatti L; Paolino E; Tola MR; Granieri E; Baricordi OR
J Neuroimmunol; 2004 Mar; 148(1-2):206-11. PubMed ID: 14975603
[TBL] [Abstract][Full Text] [Related]
11. Long time interval between multiple sclerosis onset and occurrence of primary Sjögren's syndrome in a woman treated with interferon-beta.
De Santi L; Costantini MC; Annunziata P
Acta Neurol Scand; 2005 Sep; 112(3):194-6. PubMed ID: 16097964
[TBL] [Abstract][Full Text] [Related]
12. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
[TBL] [Abstract][Full Text] [Related]
14. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
Boz C; Oger J; Gibbs E; Grossberg SE;
Mult Scler; 2007 Nov; 13(9):1127-37. PubMed ID: 17967840
[TBL] [Abstract][Full Text] [Related]
15. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial.
Panitch H; Goodin D; Francis G; Chang P; Coyle P; O'Connor P; Li D; Weinshenker B;
J Neurol Sci; 2005 Dec; 239(1):67-74. PubMed ID: 16169561
[TBL] [Abstract][Full Text] [Related]
16. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
Pokryszko-Dragan A; Bilińska M; Gruszka E; Dubik-Jezierzańska M
Pol Merkur Lekarski; 2005 Nov; 19(113):654-8. PubMed ID: 16498805
[TBL] [Abstract][Full Text] [Related]
17. Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?
Sorensen PS; Koch-Henriksen N; Bendtzen K
Mult Scler; 2007 Jun; 13(5):616-21. PubMed ID: 17548440
[TBL] [Abstract][Full Text] [Related]
18. Time of interferon-beta 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients.
Kümpfel T; Schwan M; Pollmächer T; Yassouridis A; Uhr M; Trenkwalder C; Weber F
Mult Scler; 2007 Nov; 13(9):1138-45. PubMed ID: 17967841
[TBL] [Abstract][Full Text] [Related]
19. [Interferon-beta 1a in relapsing-remitting multiple sclerosis. First report of a Mexican population].
León C; Violante A; Arriada N; Santana HR; Corona T
Rev Neurol; 2000 Dec 1-15; 31(11):1019-22. PubMed ID: 11190865
[TBL] [Abstract][Full Text] [Related]
20. Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b.
Baum K; O'Leary C; Coret Ferrer F; Klímová E; Procházková L; Bugge J;
Mult Scler; 2007 Nov; 13(9):1153-60. PubMed ID: 17967843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]